A Phase I Study to Assess the Food Effect on the Pharmacokinetics of Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic ER+ Breast Cancer and Men and Women With Progressive Non-Small Cell Lung Cancer
Phase of Trial: Phase I
Latest Information Update: 07 Jul 2016
At a glance
- Drugs Entinostat (Primary) ; Erlotinib; Exemestane
- Indications Advanced breast cancer; Non-small cell lung cancer
- Focus Pharmacokinetics
- Sponsors Syndax Pharmaceuticals
- 29 Jun 2016 Status changed from active, no longer recruiting to completed.
- 03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
- 09 Sep 2013 Planned End Date changed from 1 Dec 2013 to 1 May 2014 as reported by ClinicalTrials.gov.